AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in infants
Rehovot, Israel – 19 January 2014 – Advanced Inhalation Therapies (AIT), a leader in the development of nitric oxide (NO) therapeutics for the treatment of infectious respiratory diseases, announced today that its lead investigator will present clincial trial results at the upcoming 2014 American Thoracic Society (ATS) International Conference Committee in San Diego, California, May16 to 21, 2014.
The presentation entitled “Prospective, double-blind, randomized controlled trial, evaluation of the safety and tolerability of intermittent high-dose inhaled nitric oxide in infants with acute bronchiolitis,” will be given by Professor Asher Tal, M.D., the principal investigator of the trial. Professor Tal is a professor of pediatrics and Head of the Department of Pediatrics B at Soroka University Medical Center, Israel.
As part of the presentation, Professor Tal will review the Company’s Phase II clinical trial mid study results for acute bronchiolitis.
The presentation is scheduled for Sunday, May 18, 2014, as part of the A28 session; “ What is new in lung development and early life infection? “
About Nitric Oxide
Nitric oxide is a small, unstable, naturally produced gas that acts as an anti-infection agent, efficient in treating a wide range of diseases. AIT uses nitric oxide in unique dosages and modes of delivery to enable direct, effective access to the lungs.
AIT (http://www.ait-pharm.com) is a drug development company focused on the development and commercialization of nitric oxide formulations for the treatment of infectious respiratory diseases such as bronchiolitis, cystic fibrosis, pneumonia, and asthma. The Company was founded by Mor Research Applications, a subsidiary of Clalit Health Services, Israel’s largest health management organization. AIT is currently recruiting cystic fibrosis patients for Phase II trials.
Racheli Vizman, COO, AIT
2 Derech Meir Weisgal
Rehovot 9632605, Israel
Direct: +972 8 684 3313